Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer

Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer

Nivolumab is an anti-PD1 antibody, given in second-line or later treatment in advanced non-small cell lung cancer (NSCLC). The objective of this study was to describe the predictive value of circulating tumor DNA (ctDNA) on the efficacy of nivolumab in advanced NSCLC. We prospectively included all c...

Full description

Bibliographic Details
Main Authors: Etienne Giroux Leprieur, Guillaume Herbretau, Coraline Dumenil, Catherine Julie, Violaine Giraud, Sylvie Labrune, Jennifer Dumoulin, Julie Tisserand, Jean-François Emile, Hélène Blons, Thierry Chinet
Format: Article
Language:English
Published: Taylor & Francis Group 2018-05-01
Series:OncoImmunology
Subjects:
nivolumab
circulating tumor dna
anti-pd1
immune checkpoint inhibitor
tumor response
clinical benefit
somatic mutation
non-small cell lung cancer
next-generation sequencing
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1424675

Internet

http://dx.doi.org/10.1080/2162402X.2018.1424675

Similar Items